4528:TYO
Ono Pharmaceutical Co Ltd
2 290,00 JP¥
arrow_downward
-1,84%(-43,00) 1D
2 қаз., 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4528...
Open
2 318 JP¥
High
2 321 JP¥
Low
2 290 JP¥
Mkt. cap
1,14 трлн
Avg. vol.
1,47 млн
Volume
1,50 млн
Dividend
3,49%
Quarterly dividend
20 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
14,12
52-wk high
2 674 JP¥
52-wk low
1 678 JP¥
EPS
162 JP¥
Shares outstanding
514,12 млн
No. of employees
4 мың
Open
2 318 JP¥
High
2 321 JP¥
Low
2 290 JP¥
Mkt. cap
1,14 трлн
Avg. vol.
1,47 млн
Volume
1,50 млн
Dividend
3,49%
Quarterly dividend
20 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
14,12
52-wk high
2 674 JP¥
52-wk low
1 678 JP¥
EPS
162 JP¥
Shares outstanding
514,12 млн
No. of employees
4 мың
News stories
From web sources and news partners
Renaissance Capital
·
30 минут бұрын
GBC IPO News - Atlanta area bank Georgia Banking Company files for a direct listing on the Nasdaq
Crowdfund Insider
·
14 минут бұрын
XRP Treasury Firm Evernorth Clears Shareholder Vote Ahead Of Oct 8 Nasdaq Debut
The Business Journals
·
29 минут бұрын
NYSE suspends trading in Oregon public company once valued at $2B
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4,21 мың
Founded1717
HeadquartersОсака, Osaka, Жапония
SectorPharmaceutical industry
Websiteono-pharma.com